Where does subclinical hypothyroidism start? Implications for the definition of the upper reference limit for thyroid stimulating hormone;Wo beginnt die subklinische hypothyreose? Implikationen zur definition der oberen referenzgrenze für thyreotropin

NuklearMedizin

Volumn 44, Issue 2, 2005, Pages 56-61

  Zöphel, Klaus ^a,b   Wunderlich, G ^a   Gruning Th ^c   Koch, R ^b   Doge H ^a   Kotzerke, J ^b  

^a KLINIKUM CHEMNITZ   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Subclinical hypothyroidism; Thyroid gland; Thyroid stimulating hormone; TSH reference range

Indexed keywords

THYROID ANTIBODY; THYROTROPIN;

ARTICLE; AUTOIMMUNE DISEASE; ECHOGRAPHY; GERMANY; HASHIMOTO DISEASE; HORMONE DETERMINATION; HUMAN; HYPOTHYROIDISM; IODINE DEFICIENCY; MAJOR CLINICAL STUDY; REFERENCE VALUE; THYROID DISEASE;

EID: 17144381676     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623926     Document Type: Article

References (34)

1. Bergoglio LM, Vilchez PE, Fatemi S et al. TPOAb Assay Limitations may be responsible for the skew in the upper reference limit. Latin American Thyroid Society 2003, Cordoba, Argentina. Abstract # 123.
2. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease - clinical applications. JAMA 2004; 291: 239-43.
3. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 45-56.
4. Dietlein M, Dressler J, Farahati J et al. Procedure guideline for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin 2004; 43: 115-20.
5. Dietlein M, Schober O, Schicha H. Overtherapy or undertherapy for papillary thyroid microcarcinoma? Nuklearmedizin 2004; 43: 107-14.
6. Dietlein M, Dressler J, Grünwald F et al. Guideline for in vivo- and in vitro procedures for thyroid diseases (version 2). Nuklearmedizin 2003; 42: 109-15.
7. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for radioiodine test (version 2). Nuklearmedizin 2003; 42: 116-9.
8. Dietlein M, Dressier J, Eschner W et al. Procedure guideline for thyroid scintigraphy (version 2). Nuklearmedizin 2003; 42: 120-2.
9. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2). Nuklearmedizin 2003; 42: 123-5.
10. Dietlein M, Moka D, Schmidt M et al. Prevention, screening and therapy of thyroid diseases and their cost-effectiveness. Nuklearmedizin 2003; 42: 181-9.
11. Görges R, Brandt-Mainz K, Freudenberg L et al. Continously increasing sensitivity in thyroid cancer aftercare in the course of three generations of thyroglobulin IMAs. Nuklearmedizin 2003; 43: 157-66.
12. Hollowell JG, Staehling NW, Hannon WH et al. Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): NHANES III. J Clin Endocrinol Metab 2002; 87: 489-99.
13. Imaizumi M, Akahoshi M, Ichimaru S et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89: 3365-70.
14. King C, Ilic A, Koelsch K et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117: 265-77.
15. Löffler M, Weckesser M, Franzius C et al. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 2003; 42: 240-3.
16. Pedersen OM, Aardal NP, Larssen TB et al. The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 2000; 10: 251-9.
17. Pirnat E, Zaletel K, Gaberscek S et al. Early changes of thyroid hormone concentrations after 131I therapy in Graves' patients pretreated or not with methimazole. Nuklearmedizin 2004; 43: 129-34.
18. Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases. Eur J Endocrinol 2004; 150: 605-18.
19. Prummel MF, Wiersinga WM. Thyroid autoimmunity and miscarriage. Eur J Endocrinol 2004; 751-5.
20. Reinhardt M, Schümichen C, Schächtele S et al. Assessment of basal and stimulated TSH in overt and subclinical hyperthyroidism. Nuklearmedizin 1995; 34: 61-5.
21. Roden M, Nowotny P, Vierhapper H et al. Diagnostic relevance of suppressed basal concentrations of TSH compared with the negative TRH test in detection and exclusion of hyperthyroidism. Acta Endocrinol 1991; 124: 136-42.
22. Sahlmann CO, Siefker U, Lehmann K et al. Quantitative thyroid scintigraphy for the differentiation of Graves' disease and hyperthyroid autoimmune thyroiditis. Nuklearmedizin 2004; 43: 124-8.
23. Schicha H, Reiners Chr, Moser E et al. Subclinical thyroid disease. Nuklearmedizin 2004; 43: 69-71.
24. Sharp D. Whose normal thyroid function is better - yours or mine? Lancet 2002; 360: 353-4.
25. Spencer CA. Subclinical Hypothyroidism and TSH - New Aspects on TSH Reference Values. Guest Lecture anlässlich der Tagung Schilddrüse Heidelberg 2003; Berlin: De Gruyter 2004.
26. Spencer CA. National Academy of Clinical Biochemistry. Consensus Guidelines. 2003: Guideline 22 and 27.
27. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42: 140-5.
28. Spencer CA, Takeuchi M, Kazarosyan M et al. Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH. Clin Chem 1995; 41: 367-74.
29. Spencer CA, Schwarzbein D, Guttler RB et al. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. J Clin Endocrinol Metab 1993; 76: 494-8.
30. Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease - scientific review and guidelines for diagnostic and management. JAMA 2004; 291: 228-38.
31. Taimela E, Taehtelae R, Koskinen P et al. Ability of two new thyrotropin (TSH) assays to separate hyperthyroid patients from euthyroid patients with low TSH. Clin Chem 1994; 40: 101-5.
32. Zöphel K, Saller B, Wunderlich G et al. Autoantibodies to Thyroperoxidase (TPOAb) in a Large Population of Euthyroid Subjects: Implications for the Definition of TPOAb Reference Intervals. Clin Lab 2003; 49: 591-600.
33. Zöphel K, Wunderlich G, Kopprasch C et al. Predictive value of thyrotropin receptor antibodies (TRAb) using the second generation TRAb human assay after radioiodine treatment in Graves' disease. Nuklearmedizin 2003; 42: 63-70.
34. Zöphel K, Pinkert J, Wunderlich G et al. Can immunoradiometric measurement of Serum Thyrotropin (TSH) compete with a luminometric assay? Nuklearmedizin 1999; 38: 150-5.